Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DEP as an Initial Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis
NCT02912702Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Sep 2016
- Primary completion
- Sep 2018
- Modality
- Therapeutic Enzymes, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of pegaspargase, pegylated liposomal doxorubicin, etoposide and methylprednisolone in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Overall Response Rate at 8 weeks. Status: unknown.
02
Drugs
pegaspargasepegylated liposomal doxorubicinetoposidemethylprednisolone
03
Conditions
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH)
Beyond the preview
Go deeper on NCT02912702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912702.